KemPharm is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.
Dr. Lauderback has served as KemPharm’s Vice President, Manufacturing since March 2016, having previously held the position of Vice President, Commercial Operations since September 2012. Prior to joining KemPharm, Dr. Lauderback was the Senior Manager of CMC Scientific Affairs at Sigma-Tau Pharmaceuticals, Inc., a specialty pharmaceutical company, from June 2009 to September 2012. From 2008 to 2009, Dr. Lauderback worked as the Director of Product Development at AirBase Therapeutics, LLC. Dr. Lauderback started his career at New River Pharmaceuticals, where he served as a Senior Scientist from 2001 to 2006 and as the Associate Director, CMC Development from 2006 to 2007.
Dr. Lauderback received his Ph.D. degree from the University of Kentucky and his B.S. degree from Emory and Henry College.